The synthesis of GLP-1 in other areas of the brain plays a vital role in providing neuroprotection and suppressing neuroinflammation through the activation of GLP-1R
IGF-1 axis: in animal model research, GH-axis stimulation by CJC-1295 + ipamorelin has been associated with downstream increases in IGF-1, the principal mediator of many of GH's tissue effects
Exenatide was the worlds first clinically used GLP-1RA, developed in 1995 and approved for the treatment of type 2 diabetes mellitus (T2DM) in 2005 due to its proven ability to regulate postprandial glucose levels effectively (DeFronzo et al., 2005
Full Ingredient List Caprylic/Capric Triglyceride, Jojoba Esters, Simmondsia Chinensis (Jojoba) Seed Oil, Theobroma Cacao (Cocoa) Seed Butter, 3-O-Ethyl Ascorbic Acid, Resveratrol, Tocopheryl (Vitamin E) Acetate, Ozokerite Wax, Phenoxyethanol, and Ethylhexylglycerin
GLOW focuses more on collagen and remodeling pathways, while KLOW adds an additional research dimension with KPV for inflammation-response signaling
Phase 2 clinical trial data published in the New England Journal of Medicine showed up to 24.2% body weight reduction at 48 weeks the highest ever reported in any obesity clinical trial
